ENINGIOMAS account for approximately 20% of all primary tumors in adults. 8, 11, 25 Most tumors are sporadic; however, NF2, an inherited disease, is associated with an increased risk for the development of meningiomas. 17, 18, 32, 35 In contrast to those in adults, childhood meningiomas account for less than 3% of all primary CNS tumors and have been reported to show a slight male predominance. 5, 6, 12, 13, 16, 20, 29, 31, 34 Although meningiomas represent the most common dura-based neoplasm in the pediatric population, they have a predilection for occurring in unusual sites such as intraventricular and infratentorial regions. [3] [4] [5] 9, 29, 33, 34, 40, 42, 46 Multifocal tumors, usually encountered in the context of NF2, are a recognized feature within the pediatric population, underscoring further differences from their adult counterparts. 14, [17] [18] [19] 33, 34 In 2000, the WHO adopted new criteria for the grading and classification of meningiomas. 26 These revised criteria and the prognostic significance of newer morphological variants (for example, rhabdoid and chordoid tumors) are now well-established guidelines for evaluating meningiomas in the adult population. Little is known about the frequency and prognostic importance of these morphological variants in childhood cases. 7, 10, 22, 25, 27, 36, 44, 45 With these observations in mind, we undertook this study to examine various clinicopathological factors that influence tumor recurrence and survival, including the new WHO grading criteria, in a large retrospective cohort. Object. The occurrence of meningiomas in children younger than 20 years of age is rare, accounting for less than 3% of all childhood tumors of the central nervous system. The authors of this study sought to add to the limited available information regarding clinicopathological factors that influence outcome, disease progression, and survival in children with meningiomas.
Clinical Material and Methods

Patient Selection Criteria
This is a retrospective study of 87 patients with CNS meningiomas from two institutions. A total of 197 patients with meningiomas that developed within the first two decades of life were identified in the files of the AFIP during the period between 1970 and 1992. The records of 72 children and adolescent patients (2.9% of 2514 patients Յ 20 years with primary CNS tumors and 5.9% of 1226 patients of all ages with meningiomas who presented during this period at the AFIP) with sufficient pathological material to confirm the diagnosis were selected for further study. The records from each case were reviewed in detail, and questionnaires were mailed to the medical records department of the referring institution and, in some cases, to the primary physicians. Data obtained in an additional 15 patients identified between 1989 and 2004 were collected from the database of the Department of Pathology at the CNMC in Washington, DC. A total of 1534 patients with brain tumors presented to CNMC during this period. Medical records were similarly reviewed, and supplemental clinical information was obtained from each patient's physicians.
The recorded clinical data included patient age, sex, history of significant comorbidity, radiotherapy for and history of NF2, location of the tumor, date of surgery for primary and recurrent resections, extent of resection, and date of recurrence based on radiological findings. The extent of resection was assessed as subtotal or gross total based on the surgical or radiographic information coded in the patient's chart. Disease progression was defined as the appearance of recurrent tumor tissue after GTR or the growth of residual tumor tissue after partial resection.
Results of Histopathological Review
In all cases, formalin-fixed and paraffin-embedded microscopic sections stained with H & E were available for review. In some cases, additional histochemical specimens were treated with other stains such as trichrome, reticulin, and periodic acid-Schiff. The following immunohistochemical stains were also provided: epithelial membrane antigen, Ki-67, cytokeratin, vimentin, and glial fibrillary acidic protein.
Classification of the histological subtypes of the meningiomas was performed using the revised WHO criteria. These categories consisted of meningothelial, fibrous, transitional, psammomatous, angiomatous, microcystic, secretory, clear cell, chordoid, papillary, lymphoplasmocyte-rich, rhabdoid, and metaplastic. A WHO grade of I, II, or III was assigned to each patient based on the morphological subtype noted earlier and the presence of atypical or anaplastic features. The designation "atypical" was predicated on the presence of four or more mitotic figures per 10 hpf or brain invasion and/or at least three of the five following variables: sheetlike growth pattern, small-cell formation, prominent nucleoli, necrosis, and hypercellularity. Neoplasms exhibiting either chordoid or clear cell features were designated as Grade II; those with either papillary or rhabdoid features received a Grade III designation. Other histopathological features that merited a Grade III designation were the following: 1) 20 or more mitoses per 10 hpf; or 2) a meningioma with other obvious malignant findings (such as a carcinoma-, sarcoma-, or melanoma-like appearance).
Statistical Analysis
The following potential prognostic factors were analyzed: age, sex, WHO tumor grade, extent of resection (partial, gross-total, or none/unknown), history of radiotherapy, and presence of comorbidity. Nine of the patients with known comorbidities had NF2, thus this condition was treated as a separate prognostic factor. The percentage of deaths was calculated for each category among the 85 patients with known mortality status at the end of the study. For the 62 patients with known survival or follow-up times, survival probabilities were calculated according to the Kaplan-Meier method and were measured from the date of diagnosis until the date of last follow up or death. Time to recurrence was measured from the date of diagnosis until the date of recurrence or last follow up. Bivariate associations between survival or recurrence and prognostic factors were tested using the log-rank test, and multivariate associations were assessed using the Cox proportional hazards regression. A two-sided probability level of 0.05 was chosen for statistical significance. Statistical analysis was performed using SPSS for Windows (version 11.0; SPSS, Inc., Chicago, IL).
Results
Results by Age and Sex
The clinicopathological results of the current analysis are summarized in Table 1 . There were 52 male (60%) and 35 female (40%) patients ranging in age from 5 months to 20 years. In the category of patients with tumors localized within the spinal compartment, five were female (83%). Six patients (7%) were 5 months to 5 years old. The overall mean age at presentation was 14 years (a mean of 14 and 13 years for male and female patients, respectively). Of the patients with known survival or follow-up times, 34% were 12 years of age or younger, 42% were 13 to 17 years of age, and the remainder (24%) were older.
Summary of Signs and Symptoms
The most common clinical presentations were seizures (33%), headaches (13%), ataxia (10%), and hemiparesis (10%). Three cases were detected during routine surveillance in patients who had a history of cancer, and one tumor was discovered as an incidental finding on neuroimaging in a patient evaluated for head trauma. In three other patients, a scalp mass heralded the diagnosis of meningioma.
Comorbidity, History of Radiotherapy, and Genetics
Nine patients had a known history of NF2, two had Gorlin syndrome, and one had Down syndrome. Eight patients had harbored neoplasms that included medulloblastomas/ primitive neuroectodermal tumors (four), schwannomas (three), astrocytoma (one), and retinoblastoma (one). One patient had acute lymphoblastic leukemia treated with a bone marrow transplant and a history of papillary thyroid carcinoma (the diagnosis of the disease had been made 8.5 years prior to the discovery of the meningioma). A 17-year-old boy with lymphoplasmocyte-rich meningioma had anemia, monoclonal gammopathy, and multiple endocrine abnormalities. In a 19-year-old man with a parietal meningothelial meningioma who was lost to follow up, there was a history of an astrocytoma, but no further clinical or pathological details were available.
A history of radiotherapy was noted in seven patients (one from the AFIP and six from CNMC). Eight occurrences of meningioma were identified in six children treated at CNMC; in all cases, the tumors were surgically confirmed. The histologically confirmed meningiomas occurred between 6.25 and 16 years after radiotherapy, with a median interval of 11 years. Six cortical lesions occurred at a median of 13.4 years (range 8.5-18 years) after a mean dose of 2496 cGy at the site of tumor occurrence. Two meningiomas recurred in children who also had Gorlin syndrome. Bilateral CPA tumors developed in one child 1 year apart, at 6.25 and 7.25 years after radiotherapy. These meningiomas occurred at the edge of a 5340-cGy field of radiotherapy for a posterior fossa tumor. Four patients had medulloblastomas, one had a retinoblastoma, and one underwent radiotherapy for acute lymphocytic leukemia. Interestingly, five patients had undergone radiation treatment prior to 5 years of age as well as two at 2 years of age. No information is available regarding the clinical history of the only case from AFIP.
Location of Tumors
In most instances (64%), tumors were dura-based and supratentorial. Fourteen tumors (16%) were infratentorial, with one patient presenting with bilateral CPA meningiomas. Overall there were 10 intraventricular tumors (12%), with seven (8%) in the lateral ventricles. Two tumors arose in the third ventricle, one of which was localized posteriorly in the pineal region. Six meningiomas (7%) arose in the extramedullary intradural spinal compartment, of which two were caudal and one lumbosacral.
Pathological Features of the Tumors
A wide spectrum of morphological variants of meningioma was encountered. There were 62 Grade I tumors (71%) consisting of 21 transitional (24%), 18 meningothelial (21%), six fibrous (7%), six psammomatous (7%), five microcystic (6%), three angiomatous (3%), and one each of secretory, lymphoplasmocytic, and metaplastic (myxoid) meningiomas. Twenty-one Grade II meningiomas (24%) consisted of 14 atypical, five clear cell, and two chordoid variants. The Grade III category (5%) comprised one anaplastic, two papillary, and one rhabdoid meningioma. Results of the immunohistochemical preparations were not entered in the statistical analysis because complete data were available for only a few cases.
Types and Results of Therapy
In 53 patients (62%), resection was believed to be complete and 28 patients (33%) underwent partial resection. In the remaining patients, the extent of resection was not reported.
Only four patients were known to have received postoperative radiotherapy. Despite GTR, a 12-year-old girl with an olfactory groove meningioma experienced two recurrences and subsequently underwent radiotherapy. An-other patient, a 19-year-old woman with a Grade I lumbosacral meningioma that was partially resected, received postoperative radiotherapy; however, she died at 137 months after the initial surgery of massive soft-tissue and bone invasion. A 12-year-old girl with a malignant parasagittal tumor experienced a recurrence at 4 months and underwent radiotherapy; nevertheless, she died at 14 months of pulmonary metastases. This patient also received chemotherapeutic agent(s), the details of which are not available. An additional patient was administered chemotherapy but was lost to follow up.
Assessment of Recurrences
Of patients in whom adequate follow-up data had been obtained, 12 experienced recurrences, three of which were ultimately fatal. In the previously mentioned 12-year-old girl with NF2 and a frontal olfactory groove meningioma (Grade I), the initial recurrence occurred at 11 months. The tumor recurred twice, 2 years apart. In a 12-year-old boy with Gorlin syndrome, a recurrence was reported 6 years after the initial diagnosis of transitional meningioma, which had been identified during a screening examination. On follow-up radiographic studies, two additional small meningiomas were identified 2 years after the first recurrence.
Seven of the 15 patients treated at CNMC did not have an associated comorbid condition. Among these patients, there was tumor recurrence in three between 12 and 18 months after the initial tumor. One patient underwent GTR and the remaining two patients underwent subtotal resection.
Another 14-year-old boy with NF2 presented with a recurrence of a Grade I meningothelial variant at 30 months after a craniotomy. A 20-year-old man with a dura-based frontal Grade I tumor experienced a recurrence at 3 months and again at 90 months. In a 6-year-old boy who died at 108 months of complications related to a massive meningioma, multiple recurrences at unknown intervals were described. In another child, a 10-year-old girl with NF2 who harbored an intraventricular rhabdoid meningioma, the initial recurrence occurred at 12 months and the subsequent one at 180 months. The first recurrence was reported at 4 months in a 12-year-old girl with a malignant meningioma. Of special note, there were no recurrences in four patients with clear cell meningioma, with follow-up periods ranging from 12 to 98 months. Similarly, a patient with a chordoid meningioma was alive and free of disease at 46 months and one with a papillary meningioma was alive and without recurrence at 36 months.
Recurrence-free survival was significantly associated with WHO grade (Fig. 1) . One third of the patients with Grade III tumors survived 10 years, compared with 92% of patients with Grade II tumors and 70% of patients with Grade I tumors (p = 0.002). This relationship remained significant after adjusting for other prognostic factors in a Cox proportional hazards regression (p = 0.048).
Synopsis of Overall Survival
Sixty-two patients had known follow-up times, ranging from 1 to 268 months with a median of 68.5 months. Seven (11.3%) of these 62 patients died before the end of the study. Survival times for these seven patients ranged from 1 to 137 months, with half of the deaths occurring after 94 months. One patient, a 1-year-old girl with a posterior fossa papillary meningioma, died 1 month following craniotomy. A 6-year-old boy with a Grade I temporal region tumor died of cardiac arrest 1 month after a partial resection. Two female patients with intraventricular tumors died of intraoperative complications: one 5 years of age and one 20 years of age.
Tumor Grade and Survival
Kaplan-Meier curves and the log-rank test were used to examine the relationship between survival in months and prognostic factors ( Table 2) . None of the factors considered was significantly associated with survival time. There is weak evidence that patients with Grade III tumors may be at higher risk (Fig. 2) ; 97% of patients with Grade I tumors and 100% of patients with Grade II tumors survived at least 5 years, whereas only 50% of patients with Grade III tumors survived that long (p = 0.06). Alternatively, not all high-grade (II and III) meningiomas were predictably associated with an adverse outcome. One patient, a 1-year-old boy with a posterior fossa papillary meningioma, was reported as being alive and well and without recurrence at 198 months. As noted, four patients with clear cell meningiomas survived longer than expected. None of the prognostic factors was found to be significantly related to survival time in a Cox regression model assessing their joint significance (results not shown).
Discussion
Recently, Perry and Dehner 34 studied 38 cases of pediatric meningiomas and published a comprehensive review of the literature that validated many earlier observations. Although our study corroborates and extends the majority of these conclusions, not all of our findings mirror previous data. For example, we were unable to confirm the predominance of clear cell and papillary subtypes, and we did not identify tumors of parenchymal origin. Similar to findings of several earlier reports, we found a significant male predominance, with the exception of spinal cord meningiomas, which were overwhelmingly more common in female patients (83%). Alternatively, Rochat, et al., 38 recently studied 22 cases of meningiomas in children younger than 15 years of age and reported a higher number of girls with intracranial tumors and a worse-than-expected prognosis.
With respect to tumor grade and histopathological sub-types, we found that the distribution in childhood cases closely approximates that reported in the adult population. Although the "sclerosing variant" constituted a remarkable 47% of 15 pediatric meningiomas reported by one group, we did not encounter any examples. 12 The two dominant morphological patterns in the study by Perry and Dehner 34 were dura-or leptomeningeal-based masses and "neoplastic meningitis." Surprisingly, we did not identify any cases of the latter entity. As a possible explanation, these differences may reflect a bias in the literature toward submitting and reporting more unusual presentations or aggressive variants.
Most of our patients (71%) had Grade I tumors that included rare metaplastic (one) and lymphoplasmocyte-rich (one) meningioma variants. Of the 24% Grade II tumors, clear cell (five) and chordoid (two) represented only 8% of the total number of cases. Although most reports indicate a younger age at presentation for clear cell meningiomas, the four patients in our series were 16, 17, 18, and 19 years of age. 37 Only two papillary meningiomas were represented among the four Grade III tumors, one in a 1-year-old boy and another in a 13-year-old girl. A single case of a rhabdoid meningioma that arose in the lateral ventricle was identified in a 10-year-old girl with NF2. None of the tumors in our series was described in conjunction with an isolated intraparenchymal lesion.
In 1988, Kepes, et al., 25 reported on a cohort of seven children (range 8-19 years of age) with chordoid meningiomas and systemic manifestations of Castleman disease. Other authors have been unable to confirm this association, particularly in a recent review of 42 patients with chordoid meningiomas. 11 We encountered a single case of a lymphoplasmocytic meningioma in a patient with anemia and monoclonal gammopathy, an uncommon association that has been previously reported. 28 Unusual location is another feature considered unique in the pediatric cohort. Although the majority of tumors in our study were situated in the supratentorial compartment, unusual sites were well represented. Sixteen percent were infratentorial and 12% intraventricular. Among 21 Grade II tumors, a single case arose along the sphenoid wing, four cases (19%) were infratentorial, and three (14%) were spinal. There was one (25%) intraventricular and one (25%) infratentorial Grade III tumor.
Neurofibromatosis Type 2 is an autosomal-dominant disorder characterized by the occurrence of bilateral vestibular schwannomas and other benign tumors of the nervous system, including meningiomas. 32 In particular, the so-called Wishart variant is strongly associated with meningiomas as the initial manifestation of disease. 17 In approximately 60% of sporadic meningiomas in adults, the tumor suppressor gene NF2, located on chromosome 22q, is inactivated, and NF2 mutations have been specifically reported in transitional and fibrous, but not meningothelial, meningiomas. Perry, et al., 35 analyzed NF2-associated meningiomas in children and found that they share the common molecular alterations of their sporadic counterparts in adults and that a higher fraction are genotypically and phenotypically aggressive. We did not find a relationship between NF2 and outcome.
Gorlin syndrome, also known as multiple basal cell carcinoma syndrome, is another familial tumor condition with autosomal-dominant inheritance and an association with meningiomas. 2, 26 This syndrome was diagnosed in two patients in our series. One patient was a 14-year-old boy who suffered a meningioma after earlier radiotherapy for a medulloblastoma. The other patient had a similar history that included a medulloblastoma identified at 3 years of age followed by radiotherapy. Based on both the genetic predisposition and history of radiotherapy, these patients are at substantial risk for suffering subsequent meningiomas.
Exposure to ionizing radiation is another known risk factor for the development of meningiomas. 15, 21, 23, 24, 30, 39, 43 AlMefty, et al., 1 reported that the age of patients with meningiomas at presentation and the latency period of radiationinduced meningiomas are related to dose. The authors also discovered that these tumors were more aggressive, certain to recur, and more likely to be multiple and to have both a higher histopathological grade and multiple clonal aberrations, especially on chromosomes 1p, 6q, and 22. In another study, Ghim, et al., 21 described their experience with two 15-year-old patients and reviewed the clinical features of 13 additional patients. The mean age at the time of radiation treatment was 2.5 years of age and the mean latent period was 10.8 years. Similarly, Salvati, et al., 41 followed three children with acute lymphoblastic leukemia in whom radiation-induced meningiomas developed and found a mean interval of 10.4 years and no recurrences at 1, 4, and 4 years, respectively, after surgery. Strojan, et al., 43 did not confirm a correlation between radiation dose and latency period in five cases of secondary intracranial meningiomas after high-dose cranial irradiation. Of the seven patients in our study in whom radiation-induced meningiomas developed, the shortest known latency interval was 6.25 years (mean 11 years), and the mean age was 13.4 years. Although the majority of radiation-induced meningiomas occurred at least 8.5 years after radiotherapy in the patients treated at CNMC, a bilateral CPA tumor developed 6.25 and 7.25 years after radiotherapy in one child in whom 5000 cGy radiotherapy had been delivered to the posterior fossa. As in other reports, the children in whom postradiotherapy meningiomas developed after a short latency had received radiotherapy early in life. 21, 23 Except for the child with the CPA tumors, the meningiomas that developed after radiotherapy in our series did not occur in the area in which maximal radiation had been delivered, but rather in the cortex, which had received the craniospinal dose of radiotherapy (2640 cGy) rather than the higher dose (Ͼ 4500 cGy) applied to the primary tumor site. Histologically, results for postradiotherapy meningiomas did not differ from the group as a whole; the outcome after surgery alone was excellent. All except one of these patients are alive and well and exhibit no evidence of recurrence.
Biological behavior in both adult and childhood meningiomas remains notoriously unpredictable. The literature on them is replete with examples of histopathologically benign examples that recur and even metastasize. The obverse is also true: some children with frankly malignant-appearing meningiomas have surprisingly favorable outcomes. Although it was not statistically significant, we observed an overall shorter survival time among patients with Grade III tumors. Alternatively, Perry and Dehner 34 described a tumor that displayed a high-grade, fibrosarcoma-like pattern with a striking 109 mitoses per 10 hpf. Nevertheless, this patient was alive after 2.4 years, albeit with lung metastases. We found similar outliers among our cases of highgrade tumors.
Conclusions
In summary, as is the case in adults, the clinical evolution of meningiomas in children is not reliably predictable and remains problematic. Treatment in both the pediatric and adult population remains controversial but includes surgery, observation, and, in some instances, radiotherapy. Insufficient data are available regarding the role of adjuvant chemotherapy. Given the relative lack of response of these tumors to radiotherapy and potential adverse sequelae in children, it is likely that novel targeted therapeutic modalities will be introduced and tested. Additional investigations are needed to determine the optimal intervention strategy for children with meningiomas, especially those with biologically aggressive variants. Finally, this study highlights the need for close surveillance of children who have undergone prior radiotherapy and have a genetic predisposition to suffer meningiomas.
